Elevation Oncology to Participate in Upcoming Investor Conferences

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies, has announced its participation in two upcoming investor conferences in March 2025. The company will present updates on its differentiated ADC programs and upcoming milestones at these events, providing investors with valuable insights into its pipeline and strategic direction.



The company will participate in the TD Cowen 45th Annual Health Care Conference on March 4, 2025, where it will present a fireside chat at 9:10 AM ET in Boston, MA. Additionally, Elevation Oncology will participate in the Leerink Global Biopharma Conference on March 11, 2025, presenting a fireside chat at 8:40 AM ET in Miami, FL. Live webcasts and replays of both fireside chats will be available on the Events page of Elevation Oncology's Investor Relations website at .

Elevation Oncology's participation in these conferences comes at a critical juncture for the company, as it continues to advance its lead candidate, EO-3021, a potentially best-in-class, antibody drug conjugate (ADC) designed to target Claudin18.2, a clinically validated molecular target that can selectively deliver a cytotoxic payload directly to kill cancer cells. The company is working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications to demonstrate its potential, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand its novel oncology pipeline.

Insert chart showing the progress of EO-3021 in clinical trials and upcoming milestones

In the upcoming fireside chats, Elevation Oncology is expected to provide updates on its ongoing clinical trials, including the Phase 1 clinical trial of EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer. The company is also expected to share preclinical data for its HER3 ADC program, EO-1022, and provide updates on its financial guidance.

Investors will be closely watching these updates and milestones to assess the company's progress and make informed decisions about their investments in Elevation Oncology. The stock price and valuation of the company may fluctuate based on the market's perception of these updates and the company's ability to execute on its strategic plans.

In conclusion, Elevation Oncology's participation in these upcoming investor conferences is an important opportunity for the company to showcase its innovative pipeline, engage with investors, and provide valuable insights into its progress and strategic direction. As the company continues to advance its lead candidate, EO-3021, and explore new opportunities, investors will be eager to learn more about its progress and the potential of its pipeline.